1887

Abstract

Advanced melanoma cells, characterized by resistance to chemotherapy, have been shown to be highly sensitive to oncolysis by Newcastle disease virus (NDV). In the present study, we investigated the capacity of NDV to specifically infect and spread into solid tissues of human melanoma and lung carcinoma, and . For this purpose a new model of SCID-beige mice implanted with human melanoma was developed. Surprisingly, the replication competent NDV-MTH and the attenuated, single-cycle replication NDV-HUJ strains, demonstrated a similar oncolytic activity in the melanoma-implanted mice. Further, analysis, using organ cultures derived from the melanoma tissues indicated a limited spread of the two NDV strains in the tissue. Extracellular matrix (ECM) molecules, notably heparin sulfate and collagen, were found to limit viral spread in the tissue. This observation was validated with yet another solid tumour of human lung carcinoma. Taken together, the results indicate that the ECM acts as a barrier to virus spread within solid tumour tissues and that this restriction must be overcome to achieve effective oncolysis with NDV.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.043281-0
2012-08-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/8/1664.html?itemId=/content/journal/jgv/10.1099/vir.0.043281-0&mimeType=html&fmt=ahah

References

  1. Abd-Elrahman I., Hershko K., Neuman T., Nachmias B., Perlman R., Ben-Yehuda D. 2009; The inhibitor of apoptosis protein livin (ML-IAP) plays a dual role in tumorigenicity. Cancer Res 69:5475–5480 [View Article][PubMed]
    [Google Scholar]
  2. Ahlert T., Sauerbrei W., Bastert G., Ruhland S., Bartik B., Simiantonaki N., Schumacher J., Häcker B., Schumacher M., Schirrmacher V. 1997; Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 15:1354–1366[PubMed]
    [Google Scholar]
  3. Apostolidis L., Schirrmacher V., Fournier P. 2007; Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 31:1009–1019[PubMed]
    [Google Scholar]
  4. Batliwalla F. M., Bateman B. A., Serrano D., Murray D., Macphail S., Maino V. C., Ansel J. C., Gregersen P. K., Armstrong C. A. 1998; A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 4:783–794[PubMed]
    [Google Scholar]
  5. Cattaneo R., Miest T., Shashkova E. V., Barry M. A. 2008; Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6:529–540 [View Article][PubMed]
    [Google Scholar]
  6. Cheng J., Sauthoff H., Huang Y., Kutler D. I., Bajwa S., Rom W. N., Hay J. G. 2007; Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther 15:1982–1990 [View Article][PubMed]
    [Google Scholar]
  7. Choi I. K., Lee Y. S., Yoo J. Y., Yoon A. R., Kim H., Kim D. S., Seidler D. G., Kim J. H., Yun C. O. 2010; Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Ther 17:190–201 [View Article][PubMed]
    [Google Scholar]
  8. Cohen M., Braun E., Tsalenchuck Y., Panet A., Steiner I. 2011; Restrictions that control herpes simplex virus type 1 infection in mouse brain ex vivo. J Gen Virol 92:2383–2393 [View Article][PubMed]
    [Google Scholar]
  9. Csatary L. K., Eckhardt S., Bukosza I., Czegledi F., Fenyvesi C., Gergely P., Bodey B., Csatary C. M. 1993; Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17:619–627[PubMed]
    [Google Scholar]
  10. Euhus D. M., Hudd C., LaRegina M. C., Johnson F. E. 1986; Tumor measurement in the nude mouse. J Surg Oncol 31:229–234 [View Article][PubMed]
    [Google Scholar]
  11. Fábián Z., Töröcsik B., Kiss K., Csatary L. K., Bodey B., Tigyi J., Csatary C., Szeberényi J. 2001; Induction of apoptosis by a Newcastle disease virus vaccine (MTH-68/H) in PC12 rat phaeochromocytoma cells. Anticancer Res 21:1A125–135[PubMed]
    [Google Scholar]
  12. Fábián Z., Csatary C. M., Szeberényi J., Csatary L. K. 2007; p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 81:2817–2830 [View Article][PubMed]
    [Google Scholar]
  13. Freeman A. I., Zakay-Rones Z., Gomori J. M., Linetsky E., Rasooly L., Greenbaum E., Rozenman-Yair S., Panet A., Libson E., Irving C. 2006; Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221–228 [View Article][PubMed]
    [Google Scholar]
  14. Guedan S., Rojas J. J., Gros A., Mercade E., Cascallo M., Alemany R. 2010; Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18:1275–1283 [View Article][PubMed]
    [Google Scholar]
  15. Karcher J., Dyckhoff G., Beckhove P., Reisser C., Brysch M., Ziouta Y., Helmke B. H., Weidauer H., Schirrmacher V., Herold-Mende C. 2004; Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res 64:8057–8061 [View Article][PubMed]
    [Google Scholar]
  16. Kelly E., Russell S. J. 2007; History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651–659[PubMed] [CrossRef]
    [Google Scholar]
  17. Kolodkin-Gal D., Zamir G., Edden Y., Pikarsky E., Pikarsky A., Haim H., Haviv Y. S., Panet A. 2008; Herpes simplex virus type 1 preferentially targets human colon carcinoma: role of extracellular matrix. J Virol 82:999–1010 [View Article][PubMed]
    [Google Scholar]
  18. Krishnamurthy S., Takimoto T., Scroggs R. A., Portner A. 2006; Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80:5145–5155 [View Article][PubMed]
    [Google Scholar]
  19. Kunicher N., Falk H., Yaacov B., Tzur T., Panet A. 2008; Tropism of lentiviral vectors in skin tissue. Hum Gene Ther 19:255–266 [View Article][PubMed]
    [Google Scholar]
  20. Kunicher N., Tzur T., Amar D., Chaouat M., Yaacov B., Panet A. 2011; Characterization of factors that determine lentiviral vector tropism in skin tissue using an ex vivo model. J Gene Med 13:209–220 [View Article][PubMed]
    [Google Scholar]
  21. Kuriyama N., Kuriyama H., Julin C. M., Lamborn K., Israel M. A. 2000; Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther 11:2219–2230 [View Article][PubMed]
    [Google Scholar]
  22. Lazar I., Yaacov B., Shiloach T., Eliahoo E., Kadouri L., Lotem M., Perlman R., Zakay-Rones Z., Panet A., Ben-Yehuda D. 2010; The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein livin. J Virol 84:639–646 [View Article][PubMed]
    [Google Scholar]
  23. Lorence R. M., Rood P. A., Kelley K. W. 1988; Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 80:1305–1312 [View Article][PubMed]
    [Google Scholar]
  24. Lotem M., Peretz T., Drize O., Gimmon Z., Ad El D., Weitzen R., Goldberg H., Ben David I., Prus D. other authors 2002; Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). Br J Cancer 86:1534–1539 [View Article][PubMed]
    [Google Scholar]
  25. Maillard L., Ziol M., Tahlil O., Le Feuvre C., Feldman L. J., Branellec D., Bruneval P., Steg P. 1998; Pre-treatment with elastase improves the efficiency of percutaneous adenovirus-mediated gene transfer to the arterial media. Gene Ther 5:1023–1030 [View Article][PubMed]
    [Google Scholar]
  26. Massler A., Kolodkin-Gal D., Meir K., Khalaileh A., Falk H., Izhar U., Shufaro Y., Panet A. 2011; Infant lungs are preferentially infected by adenovirus and herpes simplex virus type 1 vectors: role of the tissue mesenchymal cells. J Gene Med 13:101–113 [View Article][PubMed]
    [Google Scholar]
  27. McKee T. D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J. P., Bawendi M. G., Boucher Y., Breakefield X. O., Jain R. K. 2006; Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66:2509–2513 [View Article][PubMed]
    [Google Scholar]
  28. Nachmias B., Ashhab Y., Bucholtz V., Drize O., Kadouri L., Lotem M., Peretz T., Mandelboim O., Ben-Yehuda D. 2003; Caspase-mediated cleavage converts Livin from an antiapoptotic to a proapoptotic factor: implications for drug-resistant melanoma. Cancer Res 63:6340–6349[PubMed]
    [Google Scholar]
  29. Nagai Y., Hamaguchi M., Maeno K., Iinuma M., Matsumoto T. 1980; Proteins of Newcastle disease virus. A comparison by partial protease digestion among the strains of different pathogenicity. Virology 102:463–467 [View Article][PubMed]
    [Google Scholar]
  30. Ockert D., Schirrmacher V., Beck N., Stoelben E., Ahlert T., Flechtenmacher J., Hagmüller E., Buchcik R., Nagel M., Saeger H. D. 1996; Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 2:21–28[PubMed]
    [Google Scholar]
  31. Ravindra P. V., Tiwari A. K., Sharma B., Chauhan R. S. 2009; Newcastle disease virus as an oncolytic agent. Indian J Med Res 130:507–513[PubMed]
    [Google Scholar]
  32. Schirrmacher V., Haas C., Bonifer R., Ertel C. 1997; Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 3:1135–1148[PubMed]
    [Google Scholar]
  33. Schlag P., Manasterski M., Gerneth T., Hohenberger P., Dueck M., Herfarth C., Liebrich W., Schirrmacher V. 1992; Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 35:325–330 [View Article][PubMed]
    [Google Scholar]
  34. Sinkovics J. G., Horvath J. C. 2000; Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16:1–15 [View Article][PubMed]
    [Google Scholar]
  35. Smith E., Breznik J., Lichty B. D. 2011; Strategies to enhance viral penetration of solid tumors. Hum Gene Ther 22:1053–1060 [View Article][PubMed]
    [Google Scholar]
  36. Steiner H. H., Bonsanto M. M., Beckhove P., Brysch M., Geletneky K., Ahmadi R., Schuele-Freyer R., Kremer P., Ranaie G. other authors 2004; Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22:4272–4281 [View Article][PubMed]
    [Google Scholar]
  37. Uno F., Fujiwara T., Takata Y., Ohtani S., Katsuda K., Takaoka M., Ohkawa T., Naomoto Y., Nakajima M., Tanaka N. 2001; Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res 61:7855–7860[PubMed]
    [Google Scholar]
  38. Victor R., Chauzy C., Girard N., Gioanni J., d’Anjou J., Stora De Novion H., Delpech B. 1999; Human breast-cancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronan-binding sites in metastatic cells. Int J Cancer 82:77–83 [View Article][PubMed]
    [Google Scholar]
  39. Wagner S., Csatary C. M., Gosztonyi G., Koch H. C., Hartmann C., Peters O., Hernáiz-Driever P., Théallier-Janko A., Zintl F. other authors 2006; Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 114:731–743 [View Article][PubMed]
    [Google Scholar]
  40. Watanabe Y., Kojima T., Kagawa S., Uno F., Hashimoto Y., Kyo S., Mizuguchi H., Tanaka N., Kawamura H. other authors 2010; A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene 29:1145–1154 [View Article][PubMed]
    [Google Scholar]
  41. Yaacov B., Eliahoo E., Lazar I., Ben-Shlomo M., Greenbaum I., Panet A., Zakay-Rones Z. 2008; Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther 15:795–807 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.043281-0
Loading
/content/journal/jgv/10.1099/vir.0.043281-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error